Ki67 Neoadjuvant Chem Otherapy In B Reast Cancer Evaluation Of The Efficacy And Predictive Value

Objective: To Explore the Expression of Ki67 In 72 Cases of Breast Cancer and To Analyze the Correlation of Ki67 Expression with Clinicopathological Factors and Efficacy of Neo-Adjuvant Chemotherapy. To Assess the Prediction Value of Ki67 in Selecting Neo-Adjuvant Chemotherapy.Methods: Ki67 Expression in Tumor Tissues of 72 Cases of Breast Cancer was Detected before and after Neo-Adjuvant Chemotherapy. Tumor Tissues are Achieved by Core Needle Biopsy.Results : Ki67 Overexpression was Found in those with Axillary Lymph Node(ALN) Metastasis, In Pathological Stage III and Tumor Diameter>2 Cm(P<0.05). Ki67 Expression was not Significantly Associated with Age(P>0.05). Objective Response(OR) Rate of Neo-Adjuvant Chemotherapy Was 84.2%(61/72). Patients With Ki67 Over-Expression Were More Sensitive than Those With Lower-Expression(P>0.05). Positive Expression Rate of Ki67 was Reduced Significantly by Neo-Adjuvant Chemotherapy(P<0.05). Positive Expression Rate of Ki67 was Reduced Significantly in Pathological Complete Response(PCR) Group, Clinical Complete Remission(CCR) Group and Partial Response(PR) Group.Conclusion: The Expression of Ki67 May be a Potential Predictive Biomarker for Neo-AdjuvantTherapy Response in Patients of Breast Cancer and Can Provide The Basis for Individual Therapy for Breast Cancer.